InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,465.83
(
0.02%
)
US TECH 100
19,017.20
(
-0.99%
)
Dow Jones
39,430.29
(
0.72%
)
Brent Oil
85.22
(
1.42%
)
Bitcoin
59,934.05
(
-5.11%
)
Post# of 252321
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119900
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 110781

Friday, 07/15/2011 2:56:24 AM

Friday, July 15, 2011 2:56:24 AM

Post# of 252321
Roche’s Pertuzumab shows statsig PFS in HER2+ metastatic breast cancer when added to Herceptin + Taxotere:

http://finance.yahoo.com/news/Pertuzumab-Combined-With-bw-4271582830.html?x=0&.v=1

Other details will be presented at an unspecified medical conference, and Roche will submit applications to regulatory authorities during 2011.

Pertuzumab previously showed statisg efficacy with the same cocktail in neoadjuvant HER2+ breast cancer (#msg-57628294), which was the only case I’m aware of where two mAbs + chemo showed a benefit vs one mAb + chemo.

Pertuzumab (f/k/a Omnitarg) is an HER2-dimerization inhibitor, i.e. it prevents HER2 from pairing with one of the three other kinds of HER receptors, which blocks cell signaling.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up